Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report

Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan‐Ling, Chang, Wei‐Kuo, Yen, Hao, Peng, Yi‐Jen, Chang, Wei‐Chou, Chang, Ping‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346189/
https://www.ncbi.nlm.nih.gov/pubmed/35793806
http://dx.doi.org/10.1111/1759-7714.14556
Descripción
Sumario:Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of aminotransferase levels is commonly observed during TKI treatment; however, significant hepatotoxicity is infrequent. Here, we report a patient with osimertinib‐related drug‐induced liver injury who was successfully managed with osimertinib rechallenge.

Ejemplares similares